Acne Conglobata

Acne conglobata is the severe form of acne, located on the face, back, and chest with large, painful, pus-filled cysts deep in the skin. The abscesses and sinuses result in pain, inflammation, and hypertrophic and atrophic scars. In this chapter, we aimed to clarify the pathways of acne conglobata and review the treatment options based on the literature

Lichen planus actinicus treated successfully with topical tacrolimus 0.1%: A report of six cases

Dear Editor,Lichen planus actinicus (LPA) is a photodistributed variant of lichenplanus (LP) that frequently occurs individuals with dark complexionson sun-exposed areas.1,2All of the cases admitted to our clinics forasymptomatic discoloration and rash on different parts of the faces.Five of six cases were male and one of them was female..

Evaluation of the relationship between rosacea cutaneous subtype and meibography findings

Acne rosacea (AR) is a chronic inflammatory skin disease that can cause serious ocular complications. This study was designed to evaluate dry eye disease (DED) and meibomian gland dysfunction (MGD) in AR patients and to investigate the relationship between the cutaneous subtype of AR and ocular involvement. Materials and Methods: This study included 67 participants with AR and 50 healthy individuals. Patients diagnosed with 3 cutaneous subtypes were examined: erythematotelangiectatic rosacea (ETR), papulopustular rosacea (PPR), and phymatous rosacea (PR). An ophthalmatological examination was performed that included an evaluation of lid margin alterations due to meibomian gland (MG) obstruction, Ocular Surface Disease Index assessment, tear film break-up time testing, Schirmer testing, and a corneal conjunctival fluorescein staining assessment. Meibography was used to evaluate the upper and lower lids for MG loss. Results: Findings in the AR group revealed MGD in 45.5% and DED in 28.1%. The meibomian gland loss rate (MGLR) was 38.7±16.9% and the meibomian gland loss grade (MGLG) was 1.57±0.82%. The rate of MGLR and MGLG was significantly greater in the AR group than in the control group (p<0.001). PPR was seen in 59.7% of the 67 patients, ETR in 29.9%, and PR in 13.4%. A comparison of the MGD, MGLR, MGLG, and presence of DED in the 3 cutaneous subtype groups yielded statistically insignificant results. Conclusion: AR can affect MG morphology, which may result in MGD or DED. Though we did not find a significant difference in the ocular findings by subgroup, ocular involvement is a recognized risk in AR. Ophthalmologists and dermatologists should cooperate in the evaluation of AR patients. Additional studies to further examine the effects in subtype groups are recommended

Evaluation of ocular psoriasis with meibography

Background Previous studies has shown that dry eye test abnormalities, meibomian gland dysfunction (MGD), may occur in psoriasis. Objectives The authors aimed to evaluate the dry eye disease (DED), MGD, in psoriasis patients with meibography which is a current, objective, noninvasive method for patients with meibomian gland diseases, to investigate the relationship between disease severity and ocular involvement. Methods This study included 50 participants with psoriasis and 50 healthy individuals. All subjects were examined by the same dermatologist and referred for ophthalmological examination including meibomian gland obstruction, lid margin alterations assessment, ocular surface disease index assessment, tear film break-up time test, Schirmer test, corneal conjunctival fluorescein staining assessment. Additionally, upper and lower lids were evaluated for meibomian gland loss with meibography

C-reactive protein to albumin ratio: Is a new parameter for the disease severity in patients with psoriasis vulgaris?

*Kemeriz, Funda ( Aksaray, Yazar ) *Tuncer, Sibel Çiğdem ( Aksaray, Yazar )Background: C-reactive protein to albumin ratio (CAR) is an inflammatory marker that is considered to have prognostic value in many inflammatory diseases. Objectives: In this study, we aimed to investigate whether there is a correlation between CAR value and disease severity in patients with psoriasis. Methods: The study included 70 plaque-type psoriasis patients and 67 healthy controls. CAR value was calculated after C-reactive protein (CRP) and albumin analysis was performed, Psoriasis Area and Severity Index (PASI) scores were documented. CAR value was compared with PASI scores in patient group. White blood cell count, neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, erythrocyte sedimentation rate (ESR), and mean platelet volume and CAR values were compared among these groups. We investigated the most significant parameter for disease severity. In addition, to detect relationship between CAR, disease duration and patients' age and healthy controls, correlation analysis was performed. Results: The median CAR value was found statistically significant higher in the patient group than in the control group (P < 0.001). A significant difference of median CRP, albumin, CAR (all P values are <0.001) and ESR (P = 0.024) were found among the three groups which were arranged according to the severity of the disease. Among these parameters, CAR was found as the most associated parameter with the severity of psoriasis using receiving operator characteristic analysis. Conclusion: CAR value could be a useful parameter for evaluating disease severity, management of disease activity, and follow-up strategies

Lichen planus actinicus treated successfully with topical tacrolimus 0.1%: A report of six cases

*Kemeriz, Funda ( Aksaray, Yazar ) *Kilitçi, Asuman ( Aksaray, Yazar )LETTERLichen planus actinicus treated successfully with topicaltacrolimus 0.1%: A report of six casesDear Editor,Lichen planus actinicus (LPA) is a photodistributed variant of lichenplanus (LP) that frequently occurs individuals with dark complexionson sun-exposed areas.1,2All of the cases admitted to our clinics forasymptomatic discoloration and rash on different parts of the faces.Five of six cases were male and one of them was female. Lesions ofthree male patients were on the forehead; one of these was in torm of an annular brown-violaceous plaque and two of these were inthe form of hyperpigmented patch lesion (case-1, 3, 6). Other two ofthem had hyperpigmented patch lesions on the neck (case-2, 5).Hyperpigmented patch lesions of female patient were on perioralregion (case-4). Detailed demographic and clinical features of thecases were presented in Table 1, and clinical images of the cases wereshown in Figure 1. Histopathology results of all patients reveale

The effect of isotretinoin on meibomian glands in eyes: a pilot study

The aim of this pilot study was to quantify the meibography changes in patients administered with oral isotretinoin. Methods: This prospective pilot study included 30 eyes of 30 patients who received oral isotretinoin treatment due to acne. Each patient underwent a general ophthalmological examination. After fluorescence staining of the ocular surface, the tear film break-up time (TFBUT) test, meibography and Schirmer test were carried out and noted. All of these procedures were applied before the treatment and repeated at 1, 3, and 6 months after the treatment. Results: The percentage of upper meibomian gland (MG) loss at 3 and 6 months after the treatment was 22.2% (p = 0.001) and 23.6% (p = 0.001), respectively. The percentage of lower MG loss at 3 and 6 months after the treatment was 18.7% (p = 0.001) and 20.7% (p = 0.001), respectively. The corneal fluorescein staining score at 3 and 6 months after treatment was 0.57 (p = 0.001), and 0.47 (p = 0.012), respectively. Conclusion: These findings show that oral isotretionin treatment may affect MG morphology. The study findings also suggest that isotretinoin may cause tear film instability with Meibomian gland dysfunction and may cause evaporative type of dryness

Omalizumab induced lichenoid drug eruption triggered by sun exposure

*Kemeriz, Funda ( Aksaray, Yazar ) *Ordu, Melike ( Aksaray, Yazar )Dear Editor Omalizumab is a humanized monoclonal antibody against human immunoglobulin E that is mainly indicated in asthma, allergic rhinitis, chronic spontaneous urticaria and is being increasingly used for other dermatological diseases, including atopic dermatitis, mastocytosis, hyper-IgE syndrome, and bullous pemphigoid.1,2 Rare cutaneous side effects, such as itching, skin rash, urticaria, and photosensitivity, have been reported to be associated with omalizumab use